NEW YORK, Oct. 14, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) OWN. Those investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980.
The investigation concerns whether Eiger and certain of its officers and/or directors engaged in securities fraud or other illegal business practices.
[Click here for information about joining the class action]
On September 6, 2022, Eiger published a media release “provid[ing] an update on the status of its pending Emergency Use Authorization (EUA) application of peginterferon lambda for the treatment of patients with mild to moderate COVID-19 based on its recent U.S. Food and Drug Administration (FDA) filings. ” Specifically, the company announced that “[f]Following a cooperative and extensive pre-EEA exchange of information with the FDA regarding the Phase 3 TOGETHER study of peginterferon lambda for COVID-19, the agency has indicated that it is not yet in a position to determine whether the criteria for submission of a application and issuance of an EUA are likely to be fulfilled.”
As a result of this news, Eiger’s share price fell $2.51 per share, or 29.36%, to close at $6.04 per share on September 6, 2022.
Then, on October 5, 2022, Eiger announced that it would not submit an EUA application for peginterferon lambda.
As a result of this news, Eiger’s share price fell $0.37 per share, or 5.01%, to close at $7.02 per share on October 5, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris and Tel Aviv, is recognized as one of the leading law firms specializing in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, best known as Dean of the Class Bar Association, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he founded and fights for the rights of…
